Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Hey! Dildos Sale in our Dildos Store!
Popular Articles

Comment On Dimebolin (dimebon) Increasing Brain Beta Amyloid In Mouse Models
Dimebolin, originally administered as an antihistamine, has previously been found to help slow the decline of cognitive ability in participants.
drugs without prescription
Recovery Act Funding Supports 23 Fellowships For Early Career Scientists
Funding from the American Recovery and Reinvestment Act will allow the National Institutes of Health to create jobs for early career scientists and increase the ranks of researchers and clinicians working in the global health field. With $3 million in funding over the next 18 months, the NIH"s Fogarty International Center will be able to support 23 additional participants in its Clinical Research Training Scholars and Fellows Program.
News of the day
Ghana Launches Public-Private Partnership To Control Malaria
Ghana"s Ministry of Health recently launched the Nationwide Mosquito Control Programme (NAMCOP) in conjunction with the waste management company Zoomlion Ghana Limited, the Ghanaian Chronicle/allAfrica.com reports (Akweetey, Ghanaian Chronicle/allAfrica.com, 6/19). George Sipa Yankey, Ghana"s health minister, said the government is committed to eliminating malaria and that the initiative will be part of a sustained effort so that Ghana can be the first country in West African to eliminate the disease. He said the government also plans to help the region by transferring local malaria elimination skills to other countries in West Africa.
Public Health

Sancuso(R) Clinical Trial Application Filed In China

Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the filing of clinical trial application (CTA) of SP-01 (long-acting transdermal granisetron patch; brand name: Sancuso®) to the China State Food and Drug Administration (SFDA). This represents the first regulatory-related filing in China made by Solasia. Upon SFDA approval of the application expected in the 1st quarter of 2010, Solasia will initiate Sancuso clinical trials in China through Excel PharmaStudies Inc. (http://www.excel-china.com), China"s largest Clinical Research Organization (CRO). Sancuso is the first and only commercialized long-acting granisetron transdermal product. By releasing the anti-emetic agent granisetron over a 5-day period, Sancuso reduces the need for daily dosing of injectable and oral agents. In China, Sancuso is expected to be well accepted by physicians and nurses seeking a more convenient method to prevent the debilitating effects of nausea and vomiting in patients receiving chemotherapy. As a single application provides protection over 5 days, Sancuso is expected to help reduce the duration of hospital stays of cancer patients currently receiving short-acting anti-emetic agents. About Sancuso Sancuso is a long-acting transdermal system, delivering the anti-emetic, granisetron, steadily into the patient"s bloodstream over seven days without the need for injections or swallowing pills. Granisetron is a 5-HT3 receptor antagonist with well-established efficacy against chemotherapy-induced nausea and vomiting (CINV). Sancuso was approved by the U.S. Food & Drug Administration (FDA) on September 12, 2008. Prostrakan launched Sancuso in the U.S. in the fourth quarter of 2008. Patents protecting Sancuso have been granted in the EU (2007) and Japan (2008). Solasia Pharma K.K.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009